Thursday Edition
Friday Edition

Head-to-head (to head) studies
Switching/sequencing studies
New analyses of DMT effectiveness
Use of gadolinium – consensus statement
Pregnancy rate on the increase in women with MS Read More

Thursday Edition
Saturday Edition

Teriflunomide
Dimethyl fumarate
Fingolimod
Cladribine
Alemtuzumab
Ocrelizumab

Read More

Friday Edition
Saturday Edition

Oral DMT use
Disease reactivation and miscarriage
French Canadians
Biomarkers
Concussion and MS Read More

SPECIAL REPORT

The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.

Read More